Dr. Ronald Crystal

A team led by collaborating researchers from Weill Cornell Medicine, Weill Cornell Medicine—Qatar and Qatar Foundation have assembled a large genomic database on the Qatari people, and have used it to develop an advanced but low-cost screening tool for genetic diseases in this highly distinct Middle Eastern population.

Dr. Ronald Crystal, chairman of the Department of Genetic Medicine and the Bruce Webster Professor of Internal Medicine at Weill Cornell Medicine, has been elected a fellow of the National Academy of Inventors 

The Office of Academic Integration (OVPAI) has awarded $750,000 in seed grants to 10 studies ranging from refugee health and legal rights, to a vaccine treating fentanyl addiction and overdose, to pancreatic cancer and antibiotic tolerance.

A gene therapy developed by Weill Cornell Medicine and NewYork-Presbyterian investigators helped slow progression of a rare and fatal genetic disorder in children called late infantile Batten disease, in a phase 1 clinical study.

Researchers in Doha and New York are collaborating to explore the Qatari genome.

A rapid, non-invasive eye exam that uses innovative imaging technology effectively measures the severity of disease in patients with a rare neurodegenerative disease called Friedrich ataxia, according to a study by Weill Cornell Medicine, Weill Cornell Medicine-Qatar and NewYork-Presbyterian researchers.

Levels of air pollution defined as “good” by the Environmental Protection Agency (EPA) may still harm the lungs of cigarette smokers, according to a new study conducted by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Up to 30 percent of HIV patients who are appropriately treated with antiretroviral therapies develop the chronic lung disease emphysema in their lifetime. 

Seven winners have been selected for the third round of the Daedalus Fund for Innovation awards, an innovative Weill Cornell Medicine program that helps advance promising applied and translational research projects and emerging technologies that have commercial potential. 

Weill Cornell Medical College and drug maker UCB have teamed up to translate innovative Weill Cornell-led research in bone disorders, metabolic disease and genetics into next-generation treatments.